Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Controlled Clinical Pharmacogenetic Study of a CYP2C9 Plus VKORC1 Polymorphism-Based Individualized Dosing Algorithm for Warfarin to Increase Efficiency of Achieving Therapeutic Dosing

NCT00334464 is registered in ClinicalTrials.gov with Intermountain Health Care, Inc. as lead sponsor.

NCT NCT00334464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00334464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Controlled Clinical Pharmacogenetic Study of a CYP2C9 Plus VKORC1 Polymorphism-Based Individualized Dosing Algorithm for Warfarin to Increase Efficiency of Achieving Therapeutic Dosing
Lead sponsor
Intermountain Health Care, Inc.
Phase
Not applicable
Overall status
Completed
Start date
February 28, 2006
Completion date
November 30, 2007
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, deep vein thrombosis, pulmonary embolism